RESUMO
The work described herein considers the impact of stereoelectronic effects and allylic 1,3-strain in controlling the cyclofunctionalization reaction when a hydroxyl group is at the allylic position. The stereoelectronic arguments are supported by independent iodocyclization reactions performed using two secondary alcohols. The transition-state pathways involved in these reactions are established through a comparison of relative reaction rates. A bi-directional approach is used to demonstrate the potential of the iodocyclization reaction to differentiate a terminus in molecules with a pseudo C(2) axis of symmetry, showing that two-directional synthesis can be used to differentiate between alternative transition-state pathways.
RESUMO
The strategy considered herein features an iodocyclofunctionalization/hydrogen-transfer reaction sequence for the elaboration of propionate motifs. Proceeding with excellent yield and diastereoselectivity, the synthetic sequence proposed gives access to the anti-anti dipropionate motif when the reduction step is performed under the control of the exocyclic effect. The tandem sequence is applied successfully to the synthesis of the C(7)-C(16) subunit of zincophorin, and iteration of the process gives the desired anti-anti-anti-anti polypropionate stereopentad. Modifications of the reaction sequence--including phenylselenocyclofunctionalization, carbonate hydrolysis, and chelation-controlled radical reduction reactions--lead to the formation of the anti-syn dipropionate motif with remarkable diastereocontrol.
RESUMO
Reported herein is a strategy employing a Mukaiyama reaction in tandem with a hydrogen transfer reaction for the elaboration of propionate motifs. The nature of the protecting groups on the chiral beta-alkoxy aldehyde and the type of Lewis acid used are varied to modulate the stereochemical outcome of the tandem reactions. The mode of complexation is thus controlled (monodentate or chelate) for the Mukaiyama reaction to give access to either syn or anti aldol products, precursors of the free radical reduction reaction. The endocyclic effect is subsequently capitalized upon to control the hydrogen transfer step so that the syn-reduced product may be achieved. Proceeding with excellent yield and diastereoselectivity, the synthetic sequence proposed gives access to syn-syn and syn-anti propionate motifs. Also considered is a complementary approach using a chelation-controlled Mukaiyama reaction in tandem with a free radical allylation reaction under the control of the endocyclic effect that leads to the anti-anti product.
RESUMO
[reaction: see text] A tandem process featuring intramolecular aminyl radical cyclofunctionalization and hydrogen transfer affords 2,3-trans-disubstituted pyrrolidines with anti or syn diastereoselectivity. The extension of this strategy to iminyl radicals gives trans-anti pyrrolenines with high levels of 1,2-induction in both steps of the tandem process.
RESUMO
[structure in text] The diastereoselectivity of radical processes involving 1,3-diols is increased significantly with a simple and efficient strategy using the exocyclic effect. Boronate derivatives are successfully formed in situ by treatment of an equimolar amount of Et(3)B in the presence of oxygen. This step is followed by the mediation of a carbon-centered radical alpha to the cyclic boronate to give the anti reduced product with high stereocontrol. The sequence is also extended to beta-amino alcohols.
RESUMO
The present paper reports the molecular modeling-based design and synthesis of an optically pure noncarbohydrate mimetic of sialyl Lewis X to inhibit E-selectin. Biological evaluation of the designed substance as well as that of its enantiomer gave, contrary to expectations, comparable IC50 values. Results are discussed in terms of receptor binding specificity and the molecular modeling protocol used.
Assuntos
Selectina E/efeitos dos fármacos , Oligossacarídeos/química , Receptores de Retorno de Linfócitos/efeitos dos fármacos , Sequência de Carboidratos , Modelos Moleculares , Mimetismo Molecular , Dados de Sequência Molecular , Antígeno Sialil Lewis X , EstereoisomerismoRESUMO
The synthesis, binding and photoincorporation of a thromboxane A2/prostaglandin H2 (TXA2/PGH2) analog (9,11-dimethylmethano-11,12-methano-16-(3-[125I]iodo-4-azidophenyl )-13,14- dihydro-13-aza-15 alpha beta-omega-tetranor-TXA2) [( 125I]PTA-Azido) to washed human platelets was characterized. Kinetic analysis of the binding of [125I]PTA-Azido at 30 degrees C yielded a k1 of 1.83.10(7) M-1.min-1 and k -1 of 0.195 min-1, Kd = k -1/k1 = 11 nM. Incubation of washed human platelets with [125I]PTA-Azido followed by photolysis resulted in the radiolabelling of a number of platelet proteins as assessed by SDS-PAGE autoradiography. The radiolabelling of three of these protein bands could be either uniformly blocked or reduced with a series of structurally dissimilar TXA2/PGH2 receptor antagonists or agonists and corresponded to proteins with a molecular mass of 43, 39 and 27 kDa. In addition, the incorporation of [125I]PTA-Azido into the three proteins was stereoselectively blocked by a pair of optically active stereoisomers that are TXA2/PGH2 receptor antagonists. Two-dimensional gel electrophoresis indicated that the 43 kDa protein possessed a pI value of 5.6 and that the 27 kDa protein exists in at least three isoforms with pI values of 4.9, 5.1 and 5.3. The labelling pattern was not altered by a mixture of proteinase inhibitors. The data suggest that one or more of these specifically radiolabelled proteins may represent the human platelet TXA2/PGH2 receptor.
Assuntos
Marcadores de Afinidade/síntese química , Azidas/síntese química , Plaquetas/metabolismo , Endoperóxidos de Prostaglandina/sangue , Prostaglandinas H/sangue , Receptores de Prostaglandina/metabolismo , Tromboxano A2/análogos & derivados , Tromboxano A2/sangue , Azidas/sangue , Eletroforese em Gel Bidimensional , Humanos , Técnicas In Vitro , Cinética , Fotoquímica , Ensaio Radioligante , Receptores de Tromboxanos , Receptores de Tromboxano A2 e Prostaglandina H2 , Tromboxano A2/síntese químicaRESUMO
The synthesis of a series of 2-(phenylmethyl)-4-hydroxy-3,5-dialkylbenzofurans and their inhibitory effects against leukotriene biosynthesis and 5-lipoxygenase activity in vitro are described. Many compounds in this series were found to be potent inhibitors of LTB4 production by human polymorphonuclear leukocytes with IC50 values ranging from 7 to 100 nM. Structure-activity relationships of the series are presented. Within this series, 2-[(4'-methoxyphenyl)methyl]-4-hydroxy-3-methyl-5-propyl-7-chlorobenz ofuran (L-656,224) showed extremely potent activity, inhibiting leukotriene biosynthesis in intact human leukocytes (IC50 = 11 nM), as well as the 5-lipoxygenase reaction catalyzed by cell-free preparations from rat leukocytes (IC50 = 36 nM), human leukocytes (IC50 = 0.4 microM), and the purified enzyme from porcine leukocytes (IC50 = 0.4 microM). The compound also shows oral activity in a number of animal models in vivo.
Assuntos
Araquidonato Lipoxigenases/antagonistas & inibidores , Benzofuranos/farmacologia , Inibidores de Lipoxigenase , Adulto , Animais , Benzofuranos/síntese química , Benzofuranos/uso terapêutico , Brônquios , Fenômenos Químicos , Química , Constrição Patológica/tratamento farmacológico , Constrição Patológica/imunologia , Humanos , Imunoglobulina E , Leucócitos/enzimologia , Leucotrieno B4/antagonistas & inibidores , Leucotrieno B4/sangue , Estrutura Molecular , Neutrófilos/metabolismo , Ratos , Ratos Endogâmicos , Relação Estrutura-AtividadeAssuntos
Carbazóis/farmacologia , Acetatos/farmacologia , Animais , Plaquetas/efeitos dos fármacos , Plaquetas/metabolismo , Humanos , Técnicas In Vitro , Contração Muscular/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacos , Receptores de Prostaglandina/metabolismo , Receptores de Tromboxanos , Estereoisomerismo , Relação Estrutura-Atividade , Tromboxano A2/metabolismoRESUMO
L-656,224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3-methyl-5-propyl-4-benzofuranol) was a potent inhibitor of leukotriene biosynthesis in intact rat and human leukocytes and CXBG mastocytoma cells (IC50 values, 18-240 nM) and of crude human leukocyte and highly purified porcine leukocyte 5-lipoxygenase (IC50 value, 4 X 10(-7) M). The selectivity of L-656,224 for 5-lipoxygenase was shown through the relative lack of activity of the compound on 12-lipoxygenase, 15-lipoxygenase, cyclooxygenase, catalase, and myeloperoxidase. The compound showed (i) oral activity against hyperalgesia induced in the rat paw by injection of yeast or platelet-activating factor, (ii) dyspnea in sensitized inbred rats induced by an aerosol of antigen, and (iii) bronchoconstriction induced by an aerosol of Ascaris in squirrel monkeys, suggesting a role for 5-lipoxygenase inhibitors in the treatment of asthma and peripheral pain.
Assuntos
Araquidonato Lipoxigenases/antagonistas & inibidores , Benzofuranos/farmacologia , Inibidores de Lipoxigenase , Animais , Plaquetas/enzimologia , Catalase/antagonistas & inibidores , Bovinos , Células Cultivadas , Ingestão de Alimentos/efeitos dos fármacos , Feminino , Humanos , Leucócitos/enzimologia , Neutrófilos/enzimologia , Peroxidase/metabolismo , Prostaglandina-Endoperóxido Sintases/metabolismo , Ratos , Saimiri , Glycine max/enzimologia , Especificidade da Espécie , SuínosRESUMO
Platelet-activating factor (PAF), a potent inflammatory mediator, decreases the nociceptive threshold in the rat hindpaw. Pain sensitivity, measured by the applied pressure necessary to induce vocalization, was increased maximally at 3 and 4 hr after injection of synthetic PAF. The hyperalgesic response to PAF was specifically inhibited by agents that interfere with the lipoxygenase pathway of arachidonic acid metabolism and was not affected by cyclooxygenase inhibitors. BW-755C (3-30 mg/kg, p.o.) and L-615,919 (0.01-0.3 mg/kg, p.o.) significantly reduced PAF-induced hyperalgesia, whereas indomethacin had no effect. The finding that L-615,919, a specific 5-lipoxygenase inhibitor, was a potent inhibitor of this model of hyperalgesia leads to speculation that leukotrienes are important mediators of inflammatory pain.
Assuntos
Hiperalgesia/induzido quimicamente , Hiperestesia/induzido quimicamente , Lipoxigenase/fisiologia , Fator de Ativação de Plaquetas , Animais , Relação Dose-Resposta a Droga , Feminino , Leucotrieno B4/farmacologia , Prostaglandina-Endoperóxido Sintases/fisiologia , Ratos , Ratos EndogâmicosRESUMO
L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpropa noic acid) has been studied in vitro on the guinea-pig tracheal chain, pulmonary artery and thoracic aorta ring and shown to be a potent, competitive antagonist of contractions induced by the prostaglandin endoperoxide analogue, U-44069 (pA2 values 8.0, 8.4 and 8.0 respectively). Selectivity on the guinea-pig trachea was indicated by non-competitive antagonism of contractions induced by prostaglandin D2 and minimal activity against contractions induced by leukotriene D4, prostaglandin F2 alpha, serotonin, histamine and acetylcholine. L-655,240 was a potent inhibitor of the aggregation of washed human platelets induced by U-44069 (IC50 value 7 X 10(-9) M) and inhibited aggregation of human platelet rich plasma induced by U-44069, U-46619, thromboxane A2 and collagen but not ADP or platelet activating factor. In vivo i.v. L-655,240 administered to guinea-pigs inhibited bronchoconstriction induced by i.v. U-44069 and arachidonic acid (ED50 values 0.09 and 0.23 mg kg-1) but not histamine, acetylcholine or serotonin. When administered to rhesus monkeys (3 and 10 mg/kg p.o.), L-655,240 inhibited ex vivo platelet aggregation induced by U-44069 but not ADP. It is concluded that L-655,240 is a potent, selective, orally active thromboxane/prostaglandin endoperoxide antagonist.
Assuntos
Indóis/farmacologia , Endoperóxidos de Prostaglandina/antagonistas & inibidores , Tromboxanos/antagonistas & inibidores , Animais , Cobaias , Humanos , Técnicas In Vitro , Macaca mulatta , Masculino , Músculo Liso/efeitos dos fármacos , Músculo Liso Vascular/efeitos dos fármacos , Agregação Plaquetária/efeitos dos fármacosAssuntos
Cetoácidos , Fenilbutiratos/farmacologia , Receptores de Prostaglandina/efeitos dos fármacos , Sulfonas , Aerossóis , Animais , Antígenos/imunologia , Brônquios/efeitos dos fármacos , Cobaias , Humanos , Técnicas In Vitro , Masculino , Contração Muscular/efeitos dos fármacos , Fenilbutiratos/administração & dosagem , Fenilbutiratos/metabolismo , Receptores de Leucotrienos , Receptores de Prostaglandina/metabolismo , Saimiri , Traqueia/efeitos dos fármacos , Traqueia/imunologiaRESUMO
L-648,051, sodium 4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy) propylsulfonyl]-gamma-oxo-benzenebutanoate is a selective and competitive inhibitor of [3H]leukotriene D4 (KB value of 4.0 microM) and to a lesser extent [3H]leukotriene C4 (Ki value of 36.7 microM) binding in guinea pig lung homogenates. Functionally, it selectively antagonized contractions of guinea pig trachea induced by leukotrienes C4, D4, E4, and F4 in concentrations that did not antagonize contractions induced by acetylcholine, histamine, serotonin, prostaglandin F2 alpha, or U-44069 (endoperoxide analogue). Schild plot analysis indicated that L-648,051 competitively antagonized contractions of guinea pig ileum induced by leukotriene D4 (pA2 7.7) and contractions of trachea induced by leukotrienes D4, E4, and F4 (pA2 7.3, 7.4, and 7.5, respectively). Contractions of guinea pig trachea induced by leukotriene C4 were inhibited in a noncompetitive fashion (Schild plot slope, 0.45). Developed contractions of trachea induced by the leukotrienes were rapidly reversed by L-648,051 greater than FPL-55712 greater than L-649,923. Intravenous L-648,051 selectively blocked bronchoconstriction induced in anaesthetized guinea pigs by intravenous leukotrienes C4, D4, and E4 but not that induced by arachidonic acid, serotonin, U-44069, or acetylcholine. The compound displayed poor activity following intraduodenal administration. The profile of activity for L-648,051 indicates that it may be a useful topical agent for studying the role of leukotrienes in diseases such as bronchial asthma.
Assuntos
Cetoácidos , Fenilbutiratos/farmacologia , Receptores de Prostaglandina/efeitos dos fármacos , Sulfonas , Animais , Brônquios/efeitos dos fármacos , Cobaias , Íleo/efeitos dos fármacos , Íleo/metabolismo , Técnicas In Vitro , Cinética , Masculino , Contração Muscular/efeitos dos fármacos , Receptores de Leucotrienos , Receptores de Prostaglandina/metabolismo , SRS-A/antagonistas & inibidores , SRS-A/metabolismo , SRS-A/farmacologia , Traqueia/efeitos dos fármacos , Traqueia/metabolismoRESUMO
L-649,923, Sodium (beta S*, gamma R*)-4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)- gamma- hydroxy-beta-methylbenzenebutanoate is a selective and competitive inhibitor of [3H]leukotriene D4 (Ki value of 400 nM) and to a lesser extent [3H]leukotriene C4 (Ki value of 8.6 microM) binding in guinea-pig lung homogenates. Functionally, it selectively antagonized contractions of guinea pig trachea induced by leukotriene C4, D4, E4, and F4 but not those induced by acetylcholine, histamine, serotonin, prostaglandin F2 alpha, or U-44069 (stable endoperoxide analogue). Schild plot analysis indicated a competitive inhibition of contractions of guinea-pig ileum induced by leukotriene D4 (pA2 8.1) and contractions of guinea-pig trachea induced by leukotrienes E4 and F4 (pA2 7.1 and 6.9, respectively). In contrast, contractions of guinea-pig trachea induced by leukotrienes C4 (pA2 7.2; slope 0.6) and D4 (pA2 7.2; slope 0.7) were inhibited in a noncompetitive fashion. In vivo, intravenously administered L-649,923 selectively blocked bronchoconstriction induced in anesthetized guinea pigs by leukotriene C4 and D4 (ED50 values i.v. 0.38 and 0.26 mg/kg, respectively) but not that induced by histamine, arachidonic acid, serotonin, U-44069, or acetylcholine. Following intraduodenal administration, L-649,923, blocked leukotriene D4 induced bronchoconstriction (5 and 10 mg/kg). The present findings indicate that selective antagonists, such as L-649,923, may be useful for defining the role of leukotrienes in diseases such as bronchial asthma.
Assuntos
Fenilbutiratos/farmacologia , Receptores de Prostaglandina/efeitos dos fármacos , Resistência das Vias Respiratórias/efeitos dos fármacos , Animais , Brônquios/efeitos dos fármacos , Cobaias , Íleo/efeitos dos fármacos , Técnicas In Vitro , Masculino , Contração Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Receptores de Leucotrienos , SRS-A/antagonistas & inibidores , Traqueia/efeitos dos fármacosAssuntos
Fenilbutiratos/farmacologia , Receptores de Prostaglandina/efeitos dos fármacos , Animais , Brônquios/efeitos dos fármacos , Cobaias , Íleo/efeitos dos fármacos , Técnicas In Vitro , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Contração Muscular/efeitos dos fármacos , Receptores de Leucotrienos , Receptores de Prostaglandina/metabolismo , SRS-A/metabolismoRESUMO
We have examined the effects of very pure (greater than 99.8%) chemically synthesized leukotriene B4 of verified structure on the chemotactic and secretory behavior of human polymorphonuclear leukocytes (PMN). The synthetic material is highly chemotactic and shows the same concentration dependence of this activity as does natural LTB4. Synthetic LTB4 is also a weak degranulating agent in cytochalasin B treated PMN. Maximally it released 11%, 17% and 26% as much N-acetyl-beta-D-glucosaminidase, myeloperoxidase and lysozyme as did N-formyl-methionine-leucine-phenylalanine (fMLP). Thus LTB4 differs significantly from other chemotaxins, such as C5a and fMLP, in that it is a poor secretagogue for enzymes of the specific and azurophilic granules of human PMN.